This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hwang, J. Articles by Whang-Peng, J. Search for Related Content PubMed PubMed Citation Articles by Hwang, J. Articles by Whang-Peng, J.

Studies of Topoisomerase-specific Antitumor Drugs in Human Lymphocytes Using Rabbit Antisera against Recombinant Human Topoisomerase II Polypeptide¹

Institute of Molecular Biology, Academia Sinica, Nankang, Taipei 22517, Republic of China [J. H., S. S., A. Y. C., C-C. J.], and Medicine Branch, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland 20892 [J. W-P.]

A complementary DNA fragment of the human DNA topoisomerase II gene was cloned into a T7 expression vector and overproduced in Escherichia coli. Rabbit polyclonal antibodies were raised against the recombinant topoisomerase II polypeptide which corresponds to the C-terminal one-third of human topoisomerase II polypeptide. Using the antiserum, DNA topoisomerase II levels were measured by immunoblotting human lymphocytes following phytohemagglutinin (PHA) stimulation. Our results showed that the intracellular topoisomerase II but not the topoisomerase I level increased in parallel with the entry of cells into proliferation. At least a 100-fold increase in topoisomerase II was observed at 50 h after PHA stimulation. As topoisomerase II levels increased upon PHA stimulation, DNA damage induced by teniposide (VM26) increased in parallel, as measured by both DNA synthesis inhibition and chromosomal aberrations. However, the damage induced by camptothecin also increased upon PHA stimulation, while the level of topoisomerase I remained relatively constant. Our results suggest that, in addition to cellular contents of topoisomerases, the state of cell proliferation is another important determinant of drug action.

¹ This work was supported by NIH Grant CA40884 (to Dr. Leroy F. Liu) and by the National Science Council, Republic of China.

² Predoctoral trainee of the Institute of Life Sciences, National Tsing Hua University, Republic of China.

Received 8/18/88. Revised 11/ 7/88. Accepted 11/11/88.

This article has been cited by other articles:

				L. Wei, J. Easmon, R. K. Nagi, B. D. Muegge, L. A. Meyer, and J. S. Lewis 64Cu-Azabicyclo[3.2.2]Nonane Thiosemicarbazone Complexes: Radiopharmaceuticals for PET of Topoisomerase II Expression in Tumors J. Nucl. Med., December 1, 2006; 47(12): 2034 - 2041. [Abstract] [Full Text] [PDF]

				Y. Mao, S. D. Desai, C.-Y. Ting, J. Hwang, and L. F. Liu 26 S Proteasome-mediated Degradation of Topoisomerase II Cleavable Complexes J. Biol. Chem., October 26, 2001; 276(44): 40652 - 40658. [Abstract] [Full Text] [PDF]